ReviewDer Pathologe2014
[Mutational tumor profiles beyond organ and tissue specificity: implications for diagnostics and clinical study design].
Review in Der Pathologe, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnostics and therapy of malignant tumors are based on the paradigm that cancer is an organ and tissue-specific disease. Comprehensive tumor mutation profiling data that has recently become available from next generation sequencing projects has made it possible to analyze whether the established anatomical tumor classification is reflected on the genetic level. Here, we review the results of a study on 4796 tumors of 14 major cancer types from the cancer genome atlas (TCGA) database, that on average 43% of tumors of a particular type are genetically more similar to tumors of a different anatomical origin and that the genetic tumor type corresponds to the anatomical type in only 57% of the cases. Furthermore, we discuss the implications of the complex mutation profiles and similarity patterns across cancers for diagnostics and clinical study design and explain why the comprehensive genomic data should be complemented by functional proteomic analyses.
Indexed as
Identifiers
25394977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.